enGene Holdings Inc. Common Stock (ENGN NASDAQ) stock market data APIs
$7.8274
0.49(6.3%)
as of October 17, 2025
Try our APIs with
free plan!
enGene Holdings Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Prev. Close
7.8274
Open
8.3192
High
9.6508
Low
7.8274
52 wk Range
2.7547-10.35
Market Cap
479 M
Shares Outstanding
51 192 K
EPS
-0.57
Beta
-0.262
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get enGene Holdings Inc. Common Stock data using free add-ons & libraries
Get enGene Holdings Inc. Common Stock Fundamental Data
enGene Holdings Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -100 950 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-11
- EPS/Forecast: -0.51
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
enGene Holdings Inc. Common Stock News
New
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best fast money stocks to buy now. Clear Street assumed coverage on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) with a ‘Buy’ rating and a price...
EnGene Appoints Hussein Sweiti As Chief Medical Officer
(RTTNews) - Genetic medicine company enGene Holdings Inc. (ENGN) announced Tuesday that Hussein Sweiti was appointed Chief Medical Officer, effective September 29, 2025. Sweiti is a surgical oncologi...
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regul...
enGene Holdings GAAP EPS of -$0.57
* enGene Holdings press release [https://seekingalpha.com/pr/20230067-engene-reports-third-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:ENGN [https://seekingalpha.com/symbol/E...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
